Preclinical development of a molecular clamp‐stabilised subunit vaccine for severe acute respiratory syndrome coronavirus 2Daniel Watterson, Keith J. Chappell, Koert J. Stittelaar et al.|Clinical & Translational Immunology|2021Cited by 62
Molecular clamp stabilised Spike protein for protection against SARS-CoV-2Daniel Watterson, Keith J. Chappell, Danushka K. Wijesundara et al.|Unknown|2020Cited by 15
Long-term safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2 in adults aged 18–55 years or ≥56 years: 12-month results from a randomised, double-blind, placebo-controlled, phase 1 trialKeith J. Chappell, Trent P. Munro, Francesca L. Mordant et al.|EBioMedicine|2023Cited by 6
Rapid Application of the Molecular Clamp Platform for SARS-CoV-2Daniel Watterson, Keith J. Chappell, Danushka K. Wijesundara et al.|SSRN Electronic Journal|2020Cited by 1
Long-Term Safety and Immunogenicity of an MF59-Adjuvanted Spike Glycoprotein-Clamp Vaccine for SARS-CoV-2 in Adults Aged 18–55 Years or ≥56 Years: 12-Month Results from a Randomised, Double-Blind, Placebo-Controlled, Phase 1 TrialKeith J. Chappell, Trent P. Munro, Francesca L. Mordant et al.|SSRN Electronic Journal|2023Cited by 0